(Q41447514)

30 September 2017

1 reference

title

Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes (English)

1 reference

30 September 2017

Birdsall NJ

1

1 reference

30 September 2017

Farries T

2

1 reference

30 September 2017

Gharagozloo P

3

1 reference

30 September 2017

Kobayashi S

4

1 reference

30 September 2017

Kuonen D

5

1 reference

30 September 2017

Lazareno S

6

1 reference

30 September 2017

Popham A

7

1 reference

30 September 2017

Sugimoto M

8

1 reference

30 September 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

30 September 2017

1 reference

30 September 2017

volume

60

1 reference

30 September 2017

issue

13-14

1 reference

30 September 2017

page(s)

1047-1052

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

30 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

The cholinergic hypothesis of geriatric memory dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Phase I clinical trials with WAL 2014, a new muscarinic agonist for the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

New functionally selective muscarinic agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

In vitro and in vivo evaluation of the subtype-selective muscarinic agonist PD 151832.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Allosteric regulation of cloned m1–m5 muscarinic receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Muscarinic receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Allosteric antagonists of the muscarinic acetylcholine receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Allosteric modulation of muscarinic acetylcholine receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

7 January 2021

GABAA receptor channels

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

Benzodiazepines on trial: a research strategy for their rehabilitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

The cholinergic system in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2897%2900046-5

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0024-3205(97)00046-5

1 reference

30 September 2017

1 reference